Evidence map›Paper›PMID 39455994›Full record

ArticleBMC veterinary research2024

Nesfatin-1 expression and blood plasma concentration in female dogs suffering from cystic endometrial hyperplasia and pyometra and its possible interaction with phoenixin-14.

Marta Rybska, Marek Skrzypski, Maria Billert, Tatiana Wojciechowicz, Anna Łukomska, Piotr Pawlak, Tomasz Nowak, Karolina Pusiak, Barbara Wąsowska

Abstract read
In one paragraph

Article in BMC veterinary research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Marta RybskaDepartment of Preclinical Sciences and Infectious Diseases, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland. marta.rybska@up.poznan.pl.
Marek SkrzypskiDepartment of Animal Physiology, Biochemistry and Biostructure, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland.
Maria BillertDepartment of Animal Physiology, Biochemistry and Biostructure, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland.
Tatiana WojciechowiczDepartment of Animal Physiology, Biochemistry and Biostructure, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland.
Anna ŁukomskaDepartment of Preclinical Sciences and Infectious Diseases, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland.
Piotr PawlakDepartment of Genetics and Animal Breeding, Poznań University of Life Sciences, Wołyńska 33, Poznań, 60-637, Poland.
Tomasz NowakDepartment of Internal Diseases and Diagnostics, Poznań University of Life Sciences, Wołyńska 35, 60-637, Poznań, Poland.
Karolina PusiakDepartment of Preclinical Sciences and Infectious Diseases, Poznań University of Life Sciences, Wołyńska 35, Poznań, 60-637, Poland.
Barbara WąsowskaDepartment of Physiology and Toxicology, Institute of Animal Reproduction and Food Research of Polish Academy of Sciences, Tuwima 10, Olsztyn, 10-747, Poland.

Funding

506.514.05.00 statutory fundingNational Science Centre (Poland) UMO-2021/43/O/NZ4/00275Polish Minister of Science and Higher Education Regional Initiative Excellence" in the years 2019-2022Polish Minister of Science and Higher Education Strategy of the Poznan University of Life Sciences for 2024-2026
6 · The paper itself

Abstract

backgroundNesfatin-1 is a neuropeptide that regulates the hypothalamic-pituitary-gonadal axis and may play a role in uterus function. It is co-expressed with other peptides, such as phoenixin, which can influence sex hormone secretion. Our previous research has confirmed that phoenixin-14 is involved in the development of cystic endometrial hyperplasia (CEH) and pyometra in dogs. Therefore, based on the similarities and interactions between these neuropeptides, we hypothesized that nesfatin-1 might also regulate the reproductive system in dogs. This study aimed to determine the expression of nesfatin-1 and its interaction with phoenixin-14 in dogs with CEH or pyometra compared to healthy females, and concerning animals' body condition score (BCS 4-5/9 vs. BCS > 5/9).

resultsThe analysis of nesfatin-1 in the uterus of bitches consisted of qPCR, western blot and immunofluorescence assays, and ELISAs. The results showed significantly higher nesfatin-1 encoding gene, nucleobindin-2 mRNA (Nucb2) and nesfatin-1 protein expression in overweight females and those suffering from CEH or pyometra compared to healthy animals. The immunoreactivity of nesfatin-1 was elevated in the uteri of bitches with higher BCS > 5/9. Moreover, nesfatin-1 blood concentrations increased in all examined overweight bitches. In the case of phoenixin signals, we found opposite results, regardless of the female body condition score.

conclusionThe etiology of CEH and pyometra are not fully known, although we have expanded the level of knowledge with respect to the possible interaction of nesfatin-1 and phoenixin in female dogs' uteri. They interact oppositely. With increasing female body weight, the expression of nesfatin-1 in the uterus and its peripheral blood concentration increased. However, for female dogs affected by CEH and pyometra, a decreased level of phoenixin-14, irrespective of their body condition score is characteristic. This knowledge could be crucial in the development of biomarkers for these conditions, which may lead to earlier recognition.

Indexed as

Dog DiseasesEndometrial HyperplasiaNucleobindinsPyometraAnimalsCalcium-Binding ProteinsDNA-Binding ProteinsDogsFemaleNerve Tissue ProteinsPeptide HormonesUterusCalcium-Binding ProteinsDNA-Binding ProteinsNerve Tissue ProteinsNucleobindinsPeptide HormonesBCSCanineNesfatin-1PhoenixinReproductive diseasesUterus

Identifiers

PMID39455994
PMCPMC11520108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.